2.11. 2017 BioTurku®

ArcDia launched a new IVD test

The Turku-based medical device manufacturer ArcDia International Ltd has launched a new IVD test for rapid detection of bacteria that cause antimicrobial-associated diarrhea.

The Finnish medical device manufacturer ArcDia International Ltd has launched a new IVD test for the detection of Clostridium difficile bacteria – the leading cause of antimicrobial-associated diarrhea. C. difficile is known as opportunistic bacteria that may cause life-threatening inflammation in the intestine as a complication of antimicrobial treatment. The new test application mariPOC® CDI (C. difficile infection) expands the menu of ArcDia’s mariPOC® test system.

The mariPOC® CDI test is superior to conventional tests in ease of use and reliability. The new test is automated, and thus well-suited for the analysis of large numbers of samples. It is suitable for use in clinical microbiology laboratories as well as in emergency laboratories.

The recent guidelines of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) recommends the use of phenotypic assay techniques instead of relying solely on genotypic techniques.ArcDia’s test is indeed phenotypic”, says Dr. Janne Koskinen, the Head of R&D at ArcDia.

“We believe that the new test is clinically more accurate than tests based on DNA detection. Due to its high accuracy, ArcDia’s test provides less clinically false positive results. These false positives may lead to the administration of an additional antibiotic regimen, which may further weaken the patient’s condition”, Koskinen continues.

The development of the mariPOC® CDI test is based on a productive long-term research collaboration between health care providers, clinical labs, and research institutions within a R&D program funded by Tekes – the Finnish Funding Agency for Innovation. “There has been major growth in the export of Finnish health tech products during the recent years. The new mariPOC® CDI appears to match the market needs well and we anticipate a substantial increase in ArcDia’s export business as a result”, says Dr. Aleksi Soini, ArcDia’s CEO.